Journal
DRUG DISCOVERY TODAY
Volume 20, Issue 3, Pages 353-360Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.drudis.2014.11.002
Keywords
-
Categories
Funding
- Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)
- Vice-Presidencia de Ensino, Informacao e Comunicacao/Pro-Reitoria IOC/FIOCRUZ
- Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ)
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
- Fundacao do Cancer and the Ministry of Health of Brazil
- Maeve McNicholas Memorial Foundation
Ask authors/readers for more resources
The advent and improvement of high-throughput sequencing over the past decade leveraged the study of whole genomes and transcriptomes of different organisms at lower costs. In transcriptomics, RNA-Seq expands our capacity to understand gene expression in different tissues and pathologies, and how alternative splicing might affect the final protein sequence. Here, we discuss the association of using transcriptome and proteome high-throughput data to foster drug discovery. Using this innovative strategy, some research groups have already identified computationally predicted novel peptides derived from putative splice variants in experimental human proteome data. These discoveries provide new opportunities for targeted drug development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available